Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Receivables (2016 - 2017)

Historic Receivables for Usana Health Sciences (USNA) over the last 5 years, with Q3 2017 value amounting to $6.9 million.

  • Usana Health Sciences' Receivables fell 689.98% to $6.9 million in Q3 2017 from the same period last year, while for Jul 2017 it was $6.9 million, marking a year-over-year decrease of 689.98%. This contributed to the annual value of $18.5 million for FY2016, which is 1116.76% down from last year.
  • Latest data reveals that Usana Health Sciences reported Receivables of $6.9 million as of Q3 2017, which was down 689.98% from $6.8 million recorded in Q2 2017.
  • Usana Health Sciences' Receivables' 5-year high stood at $20.9 million during Q1 2016, with a 5-year trough of $6.4 million in Q1 2014.
  • Over the past 5 years, Usana Health Sciences' median Receivables value was $7.9 million (recorded in 2016), while the average stood at $10.0 million.
  • Within the past 5 years, the most significant YoY rise in Usana Health Sciences' Receivables was 4160.1% (2016), while the steepest drop was 1872.93% (2016).
  • Quarter analysis of 5 years shows Usana Health Sciences' Receivables stood at $12.0 million in 2013, then crashed by 38.43% to $7.4 million in 2014, then grew by 18.7% to $8.7 million in 2015, then skyrocketed by 112.09% to $18.5 million in 2016, then crashed by 62.93% to $6.9 million in 2017.
  • Its Receivables stands at $6.9 million for Q3 2017, versus $6.8 million for Q2 2017 and $18.5 million for Q4 2016.